Anticompulsive effects of novel derivatives of coumarin in rats

Abstract

BACKGROUND: Until now, the neurotropic effect, in particular the effect on the emotional behavior of oxy-coumarins, has not been adequately studied. There are only few data on their central action. Currently, research is underway on the synthesis of new compounds based on natural oxy-coumarins, which will potentially have a higher biological activity.

AIM: Was to study the central action of new oxycoumarin-based compounds – IEM-2886, LVM-99, LVM-S144, in particular, on compulsive behavior in rats.

MATERIALS AND METHODS: To assess the behavior of Wistar rats, the “Marble-test” and “Elevated plus maze” methods were used. Oxycoumarin derivatives (IEM-2886, LVM-99, LVM-S144) were injected intraperitoneally at doses of 1, 10 and 25 mg/kg. The effectiveness of the drugs was judged by the number of balls buried in the “Marble test” and by the duration of staying in the open and closed sleeves of the “Elevated plus maze”. Results. It was shown that in the Marble test, oxycoumarin-based compounds (IEM-2886, LVM-99, LVM-S144) caused a decrease in the number of buried balls, which shows their anti-compulsive effect. After administration of IEM-2886, LVM-99, LVM-S144 (1–25 mg / kg) compounds, dose-dependent effects were observed (p < 0.05). The “elevated plus maze” test did not show the anxiolytic effect typical for tranquilizers. Moreover, after the administration of IEM-2886 and LVM-S144 at a dose of 25 mg / kg, an increase in the time spent in the closed sleeve of the maze (p < 0.05) was observed, i.e. an anxiogenic effect.

CONCLUSION: Thus, oxy-coumarin-based compounds are selective for the assessment of anticompulsive effects.

Keywords

oxycoumarins / Marble-test / elevated plus maze / compulsiveness / behavior

References

[1] Kashirin AO, Polukeev VA, Pshenichnaya AG, et al. Behavioral effects of new compounds based on coumarin in rat. Reviews on clinical pharmacology and drug therapy. 2020;18(1):37–42. (In Russ.) DOI: 10.7816/RCF18137-42

[2] Каширин А.О., Полукеев В.А., Пшеничная А.Г., и др. Поведенческие эффекты новых соединений на основе кумарина у крыс//Обзоры по клинической фармакологии и лекарственной терапии. 2020. Т. 18, № 1. С. 37–42. DOI: 10.7816/RCF18137-42

[3] Rodionova OM, Safonova AF, Kashirin AO, et al. The influence of new coumarin derivatives on survival rate of mice in model conditions of acute hypoxia. Medical academic journal. 2019;19(4):103–108. (In Russ.) DOI: 10.17816/MAJ19258

[4] Родионова О.М., Сафонова А.Ф., Каширин А.О., и др. Влияние новых производных кумарина на выживаемость мышей в модельных условиях острой гипоксии//Медицинский академический журнал. 2019. Т. 19, № 4. С. 103–108. DOI: 10.17816/MAJ19258

[5] Tissen IYu, Yakushina ND, Lebedev AA, et al. Effect of SB-408124, an OREX in a ox1r receptor antagonist, on the compulsive behavior and the level of anxiety after the vital stress in rats. Reviews on clinical pharmacology and drug therapy. 2018;16(1):34–42. (In Russ.) DOI: 10.17816/RCF16134-42

[6] Тиссен И.Ю., Якушина Н.Д., Лебедев А.А., и др. Эффекты антагониста OX1R рецепторов орексина А SB-408124 на компульсивное поведение и уровень тревожности после витального стресса у крыс//Обзоры по клинической фармакологии и лекарственной терапии. 2018. Т. 16, № 1. С. 34–42. DOI: 10.17816/RCF16134-42

[7] Shabanov PD, Lebedev AA, Yakushina ND, et al. Modeling the obsessive-compulsive and addictive gambling behavior in a rat marble test by means of amphetamine administration. Narcology. 2017;16(1):32–38. (In Russ.)

[8] Шабанов П.Д., Лебедев А.А., Якушина Н.Д., и др. Моделирование обсессивно-компульсивного и аддиктивного игрового поведения у крыс введением фенамина в тесте закапывания шариков//Наркология. 2017. Т. 16, № 1. С. 32–38.

[9] Albelda N, Joel D. Current animal models of obsessive compulsive disorder: an update. Neuroscience. 2012;211:83–106. DOI: 10.1016/j.neuroscience.2011.08.070

[10] Albelda N., Joel D. Current animal models of obsessive compulsive disorder: an update//Neuroscience. 2012. Vol. 211. P. 83–106. DOI: 10.1016/j.neuroscience.2011.08.070

[11] De Brouwer G, Fick A, Harvey BH, Wolmarans DW. A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive-compulsive disorder: Mapping the way forward. Cogn Affect Behav Neurosci. 2019;19(1):1–39. DOI: 10.3758/s13415-018-00653-4

[12] De Brouwer G., Fick A., Harvey B.H., Wolmarans D.W. A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive-compulsive disorder: Mapping the way forward//Cogn Affect Behav Neurosci. 2019. Vol. 19. No. 1. P. 1–39. DOI: 10.3758/s13415-018-00653-4

[13] Debeljak Z, Skrbo A, Jasprica I, et al. QSAR study of antimicrobial activity of some 3-nitrocoumarins and related compounds. J Chem Inf Model. 2007;47(3):918–926. DOI: 10.1021/ci600473z

[14] Debeljak Z., Skrbo A., Jasprica I., et al. QSAR study of antimicrobial activity of some 3-nitrocoumarins and related compounds//J Chem Inf Model. 2007. Vol. 47. No. 3. P. 918–926. DOI: https://doi.org/10.1021/ci600473z

[15] Decloedt EH, Stein DJ. Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010;6(1):233–242. DOI: 10.2147/NDT.S3149

[16] Decloedt E.H., Stein D.J. Current trends in drug treatment of obsessive-compulsive disorder//Neuropsychiatr Dis Treat. 2010. Vol. 6. No. 1. P. 233–242. DOI: 10.2147/NDT.S3149

[17] Dexeus FH, Logothetis CJ, Sella A, et al. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990;8(2):325–329. DOI: 10.1200/JCO.1990.8.2.325

[18] Dexeus F.H., Logothetis C.J., Sella A., et al. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma//J Clin Oncol. 1990. Vol. 8. No. 2. P. 325–329. DOI: 10.1200/JCO.1990.8.2.325.

[19] Egan D, O’Kennedy R, Moran E, et al. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev. 1990;22(5):503–529. DOI: 10.3109/03602539008991449

[20] Egan D., O’Kennedy R., Moran E., et al. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds//Drug Metab Rev. 1990. Vol. 22. No. 5. P. 503–529. DOI: 10.3109/03602539008991449

[21] Lake BG. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem Toxicol. 1999;37(4):423–453. DOI: 10.1016/s0278-6915(99)00010-1

[22] Lake B.G. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment//Food Chem Toxicol. 1999. Vol. 37. No. 4. P. 423–453. DOI: 10.1016/s0278-6915(99)00010-1

[23] Marazziti D, Carlini M, Dell’Osso L. Treatment Strategies of Obsessive-Compulsive Disorder and Panic Disorder/Agoraphobia. Curr Top Med Chem. 2012;12(4):238–253. DOI: 10.2174/1568026799078688

[24] Marazziti D., Carlini M., Dell’Osso L. Treatment Strategies of Obsessive-Compulsive Disorder and Panic Disorder/Agoraphobia//Curr Top Med Chem. 2012. Vol. 12. No. 4. P. 238–253. DOI: 10.2174/1568026799078688

[25] Treit D, Pinel JPJ, Fibiger HC. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav. 1981;15(4):619–626. DOI: 10.1016/0091-3057(81)90219-7

[26] Treit D., Pinel J.P.J., Fibiger H.C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents//Pharmacol Biochem Behav. 1981. Vol. 15. No. 4. P. 619–626. DOI: 10.1016/0091-3057(81)90219-7

[27] Veale D, Roberts A. Obsessive-compulsive disorder. Brit Med J. 2014;348: g2183. DOI: 10.1136/bmj.g2183

[28] Veale D., Roberts A. Obsessive-compulsive disorder//Brit Med J. 2014. Vol. 348. ID g2183. DOI: 10.1136/bmj.g2183

RIGHTS & PERMISSIONS

Daliev B.B., Bychkov E.R., Myznikov L.V., Lebedev A.A., Shabanov P.D.